| AALGX | CWICX | AALGX / CWICX | |
| Total Expense Ratio | 0.95 | 1.52 | 63% |
| Annual Report Gross Expense Ratio | 0.95 | 1.52 | 63% |
| Fund Existence | 39 years | 24 years | - |
| Gain YTD | 10.303 | 13.758 | 75% |
| Front Load | 5% | N/A | - |
| Min. Initial Investment | 2000 | 250 | 800% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 2.5B | 160B | 2% |
| Annual Yield % from dividends | 1.15 | 0.66 | 176% |
| Returns for 1 year | 10.25 | 14.79 | 69% |
| Returns for 3 years | 30.61 | 44.86 | 68% |
| Returns for 5 years | 8.22 | 30.00 | 27% |
| Returns for 10 years | 43.93 | 104.70 | 42% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FTDZX | 213.59 | 5.41 | +2.60% |
| Franklin Biotechnology Discovery Adv | |||
| MUOSX | 35.54 | -0.02 | -0.06% |
| Morgan Stanley Instl US Core R6 | |||
| PMJAX | 13.27 | -0.07 | -0.52% |
| PIMCO RAE US Small A | |||
| DFCEX | 33.87 | -0.42 | -1.22% |
| DFA Emerging Markets Core Equity 2 I | |||
| DSMDX | 24.11 | -0.64 | -2.59% |
| Driehaus Small/Mid Cap Growth | |||